Family Care Hospitals Limited has successfully concluded its postal ballot process, with shareholders approving three critical director re-appointments on February 20, 2026. The company announced the results on February 21, 2026, following a comprehensive remote e-voting exercise conducted in accordance with regulatory requirements and submitted the scrutinizer's report to BSE Limited.

Postal Ballot Results Overview

The postal ballot covered three special resolutions, all of which received strong shareholder support with 96.52% approval rate across all resolutions. A total of 85 members participated in the e-voting process, with over 10.78 million valid votes cast across the resolutions.

Detailed Voting Results and Participation

The company had sent email notifications to 43,562 members who had registered their email addresses, with the record date set as January 16, 2026. The total number of shareholders on record date was 47,300. The voting process was conducted entirely through remote e-voting, with no physical postal ballot forms distributed in compliance with MCA circulars.

Resolution-wise Voting Breakdown:

Director Appointments and Terms

Mr. Suchit Raghunath Modshing (DIN: 10974977) has been re-appointed as Executive Whole Time Director for a further term of 5 consecutive years. The resolution received overwhelming support from both promoter group (100% approval) and public shareholders.

Mrs. Archana Chirawawala (DIN: 09721625) secured her second term as Non-Executive Independent Director, while Mr. Sanjeev Seth (DIN: 10974972) was also re-appointed as Non-Executive Independent Director for his second term.

Scrutinizer Report and Regulatory Compliance

Mr. Mukesh Siroya, Proprietor of M. Siroya & Co., Practicing Company Secretaries, served as the appointed Scrutinizer for the postal ballot process. The scrutinizer was appointed by the Board of Directors on January 20, 2026, and submitted the final report on February 21, 2026, pursuant to Section 108 of the Companies Act, 2013.

The remote e-voting facility was provided by Purva Sharegistry (India) Private Limited, ensuring a fair and transparent voting process. The voting period concluded at 5:00 PM on February 20, 2026, with all resolutions achieving the requisite majority for passage. The company has submitted the scrutinizer's report and voting results to BSE Limited under Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dealmoney Commodities Private Limited has filed a revised regulatory disclosure to correct an inadvertent error in previously submitted documentation regarding its warrant acquisition in Family Care Hospitals Limited. The correction pertains to the diluted paid-up share capital figure disclosed under SEBI's substantial acquisition regulations.

Transaction Details

The warrant acquisition transaction involves significant financial parameters that demonstrate Dealmoney's strategic investment in the healthcare sector:

Share Capital Structure

The revised disclosure clarifies Family Care Hospitals' capital structure following the warrant allotment:

Regulatory Compliance

The original disclosure was submitted on December 29, 2025, under Regulation 29(1) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. Dealmoney identified the error in the diluted share capital figure and promptly filed the corrected version on January 21, 2026. The company belongs to the promoter group of Family Care Hospitals Limited, which is listed on BSE Limited under scrip code 516110.

Shareholding Position

Prior to this acquisition, Dealmoney held no shares, voting rights, or convertible instruments in Family Care Hospitals. The warrant acquisition represents the company's first substantial investment in the target company. Post-acquisition, Dealmoney's total holding stands at 1.80 crore warrants, representing 24.76% of both the total share capital and diluted voting capital.

Corporate Information

Dealmoney Commodities Private Limited operates from its registered office in Thane, Maharashtra. The revised disclosure was signed by Director Anil R Bapardekar (DIN: 10126442), emphasizing the company's commitment to accurate regulatory reporting and transparency in substantial acquisition transactions.